ST. LOUIS — Canopy BiosciencesTM, LLC, a leading provider of gene editing and personalized medicine technologies, announced today that it has launched two novel services for immuno-oncology and neurodegenerative disease. Both services allow researchers to assess the expression of nearly 800 disease-relevant genes in a single sample. The new Neuropathology service allows researchers to conduct […]

Read more

ST. LOUIS, June 28, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC, an emerging provider of gene editing and personalized medicine technologies, announced today that it has launched a service for high throughput gene expression analysis. Based on the NanoString nCounter platform, the service works with a large array of sample types, including formats such as formalin-fixed […]

Read more

Canopy Biosciences signs agreement with Cosmo Bio to sell gene engineering products in Japan ST. LOUIS, June 22, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC (“Canopy Biosciences”), an emerging provider of gene editing and personalized medicine technologies, announced a distributor agreement with Cosmo Bio Co., Ltd. (“Cosmo Bio”) for its TUNR Flexible Gene Editing technology in […]

Read more

ST. LOUIS, March 31, 2017 /PRNewswire/ — Canopy BiosciencesTM, LLC, an emerging provider of products and services for gene editing and personalized medicine, announced today that it has entered an exclusive licensing agreement with Washington University in St. Louis and Johns Hopkins for key intellectual property around a novel technology for gene editing. The TUNRTM […]

Read more